
Overview
Oncotherics Poland develops hypoxia-activated prodrugs designed to target treatment-resistant cancer cells and complement established therapies. Its lead clinical programme is AQ4N for newly diagnosed glioblastoma, while OCT1002 is a separately patented asset in advanced preclinical development.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 1 of 4 financial statements was filed late (for 2024, 17 days late). All were audited by a statutory auditor.
- 2025not filed
- 202401/08/2025
- 202305/07/2024
- 202213/07/2023
- 202114/07/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
News
OncoTherics to present company update at LSBC 2026 in Krakow
OncoTherics CEO Stefan Ogrodzinski will present the company’s latest news at the LSBC Central European Life Science Investment Conference, taking place at Hotel Stary in …
OncoTherics pitches at the 14th Texas Life Science Forum 2025
OncoTherics CEO, Stefan Ogrodzinski, was one of fifty life science and med tech companies to be selected to pitch at this years Texas Life Science …
OncoTherics to pitch at the 14th Annual Texas Life Science Forum
The Texas Life Science Forum, co-hosted by BioHouston and Rice Alliance, is the premier life science and healthtech event in Texas that brings together members …
OncoTherics visits MSKCC and MD Anderson to advance translational programme
OncoTherics’ U.S. clinical translational strategy was advanced this week through discussions with key colleagues at Memorial Sloane Kettering Cancer Centre (New York) and MD Anderson …
Industry
Offer
- Cancer drug research
- Cancer drug development
- Hypoxia-activated prodrugs
- Glioblastoma therapies
- Preclinical testing
Websites
- oncotherics.comOncoTherics | AQ4N and OCT1002 Cancer TherapeuticsWordPressGoogle AnalyticsGoogle Tag ManagerNginx
Authorized Representatives
Manner of representation
Each member of the management board is authorized to perform legal acts and submit declarations of will on behalf of the company independently.
Supervisory board
Bank accounts
Registered as a VAT taxpayer on 2019-12-01.
10 1090 2053 0000 0001 4655 8013
34 1090 2053 0000 0001 4406 1383
29 1090 2053 0000 0001 4361 9832
Debt
No entries in the National Debtors Register (KRZ).
Public aid
6 public aid cases recorded, with a total value of $2,977,240.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,075$5,075 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,823$3,823 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Nov 5, 2019 | Aid for research and development projects: industrial research | $2.1M$2,095,722 | Marszałek Małopolski |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-09-25 | Development of an innovative hypoxia-activated substance for cancer therapy | $3.1M$3,051,740 | Regional Operational Programme for the Małopolskie Voivodeship for 2014-2020 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com | ||
| Onconick sp. z o.o. | $39,587.95 | onconick.com | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| Inventro S.A. | $25,971.59 | inventro.co | ||
| Nanovelos S.A. | $24,842.03 | nanovelos.com | ||
| 4cell Therapies S.A. | $9,123.06 | 4celltherapies.com | ||
| Bioinfobank Capital sp. z o.o. | $6,252.45 | bioinfo.pl | ||
| Synerga.Fund S.A. | $3,772.65 | synergafund.com.pl | ||
| Passio Human Microbiome sp. z o.o. | $1,856.58 | passiohumanmicrobiome.com |
Change history
| Date | Event | |
|---|---|---|
| 2022-03-15 | Share capital increase (102,200.00 PLN → 104,649.20 PLN) | |
| 2021-10-27 | Entered in the register |
FAQ
Last updated: 2026-04-01